Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17873
Title: Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.
Authors: Sherry, Norelle L;Baines, Sarah L;Howden, Benjamin P
Affiliation: Antimicrobial Reference and Research Unit, Microbiological Diagnostic Unit-Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, VIC, Australia
Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, VIC, Australia
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 27-Feb-2018
EDate: 2018-02-27
Citation: International journal of antimicrobial agents 2018; online first: 27 February
Abstract: Avibactam (AVI) is a novel β-lactamase inhibitor active against class A, class C and some class D β-lactamases. In combination with ceftazidime, AVI may be useful for the treatment of infections due to Gram-negative bacteria producing carbapenemases from these classes; however, susceptibility data for some of the less common carbapenemases are limited. To assess the in vitro activity of ceftazidime/avibactam (CZA), a panel of 50 diverse carbapenemase-producing Gram-negative bacteria collected from clinical samples in Victoria, Australia, containing KPC, GES, SME, OXA-23 and OXA-48-like carbapenemases were tested for susceptibility to CZA using the broth microdilution (BMD), Etest and disk diffusion methods. All isolates were susceptible to CZA. Etest correlated well with BMD, although Etest minimum inhibitory concentrations (MICs) were generally lower than BMD. Disk diffusion correlated moderately well with BMD, with two interpretive errors. This study confirms phenotypic CZA susceptibility in the carbapenemase groups tested, including the less common OXA-23-producing Escherichia coli, SME-producing Serratia marcescens and GES-5-producing Pseudomonas aeruginosa.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17873
DOI: 10.1016/j.ijantimicag.2018.02.017
ORCID: 0000-0002-7789-8360
PubMed URL: 29499316
Type: Journal Article
Subjects: Carbapenemase-producing Gram-negatives
Ceftazidime/avibactam
GES carbapenemase
Klebsiella pneumoniae carbapenemase (KPC)
OXA carbapenemase
β-Lactamase
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.